Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-001814.pdf
0001950047-24-001814.rtf
0001950047-24-001814.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-006053.pdf
0001415889-24-006053.rtf
0001415889-24-006053.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-001497.pdf
0001950047-24-001497.rtf
0001950047-24-001497.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-24-026343.pdf
0001104659-24-026343.rtf
0001104659-24-026343.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001104659-24-024937.pdf
0001104659-24-024937.rtf
0001104659-24-024937.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-24-001197.pdf
0001558370-24-001197.rtf
0001558370-24-001197.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K

Annual report which provides a comprehensive overview of the company for the past year

 View HTML
0001558370-24-001254.pdf
0001558370-24-001254.rtf
0001558370-24-001254.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000080255-24-000713.pdf
0000080255-24-000713.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-003825.pdf
0001415889-24-003825.rtf
0001415889-24-003825.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000315066-24-001033.pdf
0000315066-24-001033.rtf